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Abstract Latent transforming growth factor-L (TGF-L) bind-
ing protein (LTBP)-1, which is easily secreted, has been shown to
enhance the secretion of TGF-L. Here we show that another
member of the LTBP family, LTBP-3, is not secreted by several
cell types, but secretion occurs after coexpression with TGF-L.
The secretion of LTBP-3 requires complexing of LTBP-3 with
Cys33 of the TGF-L propeptide. ß 2002 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
The latent transforming growth factor-L (TGF-L) binding
proteins (LTBPs-1, -2, -3, and -4) comprise a family of extra-
cellular matrix proteins. These proteins share similar modular
structures consisting primarily of multiple epidermal growth
factor (EGF)-like domains and four cysteine-rich (CR) do-
mains (also called 8-cysteine domains, or TB domains) that
are unique to LTBPs and ¢brillins. LTBP-1 was originally
found as part of a high molecular weight complex containing
TGF-L and the TGF-L propeptide [1]. During synthesis, the
N-terminal TGF-L propeptide (also called latency-associated
peptide, or LAP) is cleaved from the C-terminal mature TGF-
L. These two dimeric proteins, LAP and TGF-L, remain as-
sociated non-covalently [2,3], and can be secreted from the cell
as a small latent complex (SLC). Most cells secrete latent
TGF-L as a large latent complex (LLC) consisting of a mol-
ecule of LTBP disul¢de-bonded to the LAP of the SLC.
LTBP-1, -3, and -4 bind to LAP through cysteine residues
in the third CR domain of each of these proteins [4]. LTBP-
2 does not bind to LAP.
It is believed that LTBP-1 plays an important role in the
assembly and secretion of latent TGF-L. TGF-L that is not
associated with LTBP-1 is secreted slowly and there is im-
proper formation of disul¢de bonds [5], whereas latent
TGF-L complexed with LTBP-1 is e⁄ciently secreted and di-
sul¢de bond formation is correct. LTBP-3 may also play a
role in TGF-L secretion as mice de¢cient for LTBP-3 have
long bone defects resembling those of transgenic mice with
impaired TGF-L signaling [6]. These results have been inter-
preted to indicate that LTBP-3 regulates TGF-L bioavailabil-
ity, perhaps by a¡ecting secretion [6].
We attempted to study the biological functions of LTBP-3
in cell culture. Our e¡orts were hindered by the fact that full-
length LTBP-3, expressed in mammalian or insect cells, could
not be found in the conditioned medium. Interestingly, coex-
pression of latent TGF-L with LTBP-3 permitted secretion of
LTBP-3 as part of the LLC. By engineering various truncated
forms of LTBP-3 as well as several chimeric LTBP-1/LTBP-3
proteins, we have identi¢ed regions of LTBP-3 that regulate
its secretion. In addition, this work provides a potential mech-
anism for the requirement of LAP/TGF-L in LTBP-3 secre-
tion.
2. Materials and methods
2.1. Cell culture, antibodies and reagents
293T cells were obtained from Dr. D. Ron (NYU School of Med-
icine, New York, USA). Mouse monoclonal antibody HA.11 against
the HA tag was purchased from Babco (Richmond, CA, USA).
VB3A9 is a monoclonal antibody directed against the LAP portion
of human TGF-L1 [7]. Anti-L3C is a rabbit polyclonal antiserum
directed against the C-terminal portion of mouse LTBP-3. To gener-
ate this antibody, the cDNA fragment encoding the C-terminal por-
tion of LTBP-3 was cloned into an insect cell expression vector
pAcGP67-His [7] in frame with a 6UHis tag downstream of the
Gp67 signal sequence and expressed in insect cells. The recombinant
protein failed to be secreted and formed inclusion bodies inside the
cells. The inclusion bodies were dissolved in 8 M urea and puri¢ed
using TALON (Clontech) under denaturing conditions. The imida-
zole-eluted protein was renatured by dialysis against bu¡ers with de-
creasing concentrations of urea. Puri¢ed protein was injected into two
rabbits to produce the anti-L3C antisera. Pwo DNA polymerase and
molecular biology enzymes were purchased from Roche Molecular
Biochemicals. LipofectAMINE and LipofectAMINE PLUS reagents
were purchased from Gibco BRL.
2.2. cDNA cloning and constructs
Mouse LTBP-3 speci¢c primers were designed based on the pub-
lished sequence [8] and used in reverse transcription-PCR to amplify a
fragment (nucleotides 461^893) of mouse LTBP-3 cDNA from RNA
extracted from 2T3 cells. This fragment was used as a probe to screen
a mouse heart cDNA library (Clontech). Several clones were isolated
and cloned as EcoRI^EcoRI fragments into pBluescript SK vector.
Sequencing con¢rmed that these clones contain mouse LTBP-3
cDNA.
Human TGF-L1 cDNA was from Dr. Rik Derynck (UCSF, San
Francisco, CA, USA). Human Cys33CSer TGF-L1 cDNA (TGF-
L1C33S) was a kind gift from Dr. Jorma Keski-Oja (University of
Helsinki, Helsinki, Finland). The eukaryotic expression vector pSignal
(construct pJS34 containing nucleotides 2667^3423 of mouse LTBP-3
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cDNA) was a kind gift from Dr. Juha Saharinen (University of Hel-
sinki, Helsinki, Finland). It has a pcDNA3 backbone, a partially
optimized Kozak sequence, a mouse IgG heavy chain signal sequence,
a synthetic HA epitope and a STOP codon [9]. Fragments of the
mouse LTBP-3 or human LTBP-1 cDNA were ampli¢ed by PCR
with oligonucleotides containing appropriate restriction sites. PCR
fragments were cloned into the pSignal vector in frame with the signal
sequence at the N-terminus and the HA epitope at the C-terminus. All
constructs were veri¢ed by automated sequencing. Construct numbers
refer to the numbers listed in Fig. 3. Constructs L3CR34 (#6; nucleo-
tides 2686^3372), L3CR3 (#7; 2676^2916), L3CR4 (#8; 3201^3411),
L1CR34 (#11; 3102^3903) were generated by PCR and cloned as
BamHI-XhoI fragments into pSignal. L3 (full-length; 1^3714) was
cloned as an EcoRI^EcoRI fragment from a pBluescript SK into
the EcoRI site of pcDNA3. L3NCR4 (#1; 86^3423) was generated
by replacing the BamHI^CelII fragment of JS34 (2667^3423) with the
FseI^CelII fragment of the mouse LTBP-3 cDNA (BamHI and FseI
sites were blunted by using Klenow enzyme and T4 DNA polymerase
respectively after digestion). L3NCR2 (#2; 86^1458) was generated by
cloning the FseI^XhoI fragment (FseI site blunted after digestion) into
the BamHI (blunted), XhoI sites of pSignal. L3LEGC (#3; 1661^
3714) and L3CR3C (#5; 2686^3714) were generated by PCR with
EcoRI and XhoI sites at the ends ¢lled in, and cloned into the blunted
BamHI and XhoI sites of pSignal. L3LEGCR4 (#4; 1455^3423) was
generated by replacing the BamHI (blunted)^CelII fragment of the
construct L3CR34 with the XhoI (blunted)^CelII fragment of the
mouse LTBP-3 cDNA. L3CR3E2C (#9) was generated by cloning
the XhoI^XhoI PCR fragment of L3E2C (3394^3714) into the XhoI
site of the L3CR3 construct. L3CR4E2C (#10) was generated by
cloning the XhoI^XhoI PCR fragment of L3E2C (3394^3714) into
the XhoI site of the L3CR4 construct. L1CR34.L3E2C (#15) was
generated by cloning the XhoI^XhoI PCR fragment of L3E2C
(3394^3714) into the XhoI site of the L1CR34 construct.
L1LEG.L3CR34 (#12) was generated by cloning the BamHI^BamHI
PCR fragment of L1LEG (1326^3092) into the BamHI site of the
L3CR34 construct. L3CR34.L1E2C (#13) was generated by cloning
the XhoI^XhoI PCR fragment of L1E2C (3904^4269) into the XhoI
site of the L3CR34 construct. L3LEG.L1CR34 (#14) was generated
by cloning the BamHI^BamHI PCR fragment of L3LEG (1488^2682)
into the BamHI site of the L1CR34 construct.
2.3. Transfection and Western blot analysis
Cells were plated in 35 mm diameter tissue culture dishes at a
density of 6U105 cells per dish the day before transfection and were
transfected with 1 Wg of the indicated plasmids. Transfections were
carried out using a LipofectAMINE PLUS transfection kit (Invitro-
gen) in Opti-MEM I (Gibco BRL) following the manufacturer’s in-
structions.
The cells were washed with Opti-MEM I medium 3 h after trans-
fection, and the conditioned medium was collected 48 h after trans-
fection. The remaining cells were washed once with phosphate-bu¡-
ered saline, collected with a rubber policeman, pelletted, and lysed in
RIPA bu¡er (150 mM NaCl, 50 mM Tris, pH 7.5, 2 mM EDTA,
0.5% NP40, 0.5% Triton X-100, 0.1% SDS). Proteins in the condi-
tioned media or whole cell extract from the transfected cells were
separated by SDS^PAGE and electrophoretically transferred to nitro-
cellulose membranes. Membranes were blocked with TBS-T (Tris-
bu¡ered saline with 0.1% Triton X-100) with 5% non-fat dry milk,
incubated with primary antibody (HA.11, VB3A9 or anti-L3C) for 1 h
at room temperature, washed three times with TBS-T, and incubated
with an appropriate secondary antibody conjugated with horseradish
peroxidase (Amersham Life Science). After washing, immunoreactive
bands were revealed by processing with ECL Western blotting detec-
tion reagents (Amersham Pharmacia Biotech) following the manufac-
turer’s instructions.
3. Results
3.1. Transfection of full-length LTBP-3 in mammalian cells
caused its accumulation inside the cells
The mouse LTBP-3 protein sequence deduced from the
cDNA sequence contains a signal sequence at its N-terminus
[8], and the protein has been reported to be secreted [8,10].
However, after we transfected the full-length LTBP-3 cDNA
into 293T cells, we could not detect the protein in the condi-
tioned media using a polyclonal antibody against the C-ter-
minal region of LTBP-3 (Fig. 1). Using immunohistochemical
methods, we detected the protein as aggregates in the cytosol
(see below). The lack of secretion was not unique to 293T
cells, as expression in other mammalian cells, such as
CHOK7, 2T3, COS7 or insect cells, such as SF9 and High
5, gave similar results. Furthermore, the use of di¡erent ex-
pression vectors and/or di¡erent secretion signals did not re-
sult in the secretion of LTBP-3 (data not shown). These re-
sults suggested that the intracellular accumulation of LTBP-3
is of functional signi¢cance.
3.2. Coexpression of TGF-L1 allows the secretion of LTBP-3
LTBP-3 has been shown to bind with the TGF-L1 SLC
[4,8]. Therefore, we hypothesized that LTBP-3 secretion might
require association with latent TGF-L. To test this, we co-
transfected 293T cells with mouse LTBP-3 and human
TGF-L1 cDNAs and monitored the conditioned medium for
LTBP-3. After SDS^PAGE under non-reducing conditions,
followed by Western blotting, no protein immunoreactive
with anti-L3C was observed in the conditioned medium in
cells transfected only with LTBP-3 cDNA (Fig. 1A). How-
ever, a band at a position corresponding to 220 kDa, which
was immunoreactive with the LTBP-3 antisera (anti-L3C),
was observed when cells were transfected with TGF-L and
LTBP-3 cDNAs (Fig. 1A). A monoclonal antibody against
the LAP portion of TGF-L1 (VB3A9) revealed a band corre-
sponding to the SLC in the conditioned media (Fig. 1B). A
higher molecular mass band migrating at an apparent molec-
ular mass of more than 200 kDa corresponding to the TGF-L
LLC containing LTBP-3 was present. A truncated form of
LTBP-3, L3LEGCR4, which encodes the region starting
from the long EGF-like repeat stretch to the end of CR do-
main 4 (Fig. 3A), was also not secreted when expressed alone
(Fig. 1A), but was when coexpressed with TGF-L1 (Fig. 1B).
These data indicate that TGF-L1 assists LTBP-3 secretion by
forming a complex with LTBP-3. Coexpression of TGF-L2 or
-L3 also facilitates LTBP-3 secretion (data not shown).
Fig. 1. Coexpression with TGF-L1 helps LTBP-3 secretion. cDNAs
encoding full-length LTBP-3 or a truncated form, LEGCR4, were
transfected into 293T cells alone or together with TGF-L1 cDNA as
indicated. Conditioned media collected 48 h after transfection were
separated by SDS^PAGE under non-reducing conditions, trans-
ferred to nitrocellulose membrane and blotted either with a speci¢c
antibody for LTBP-3 (A) or with antibody against TGF-L1: LAP
(B). The positions of the SLC and the LLC are indicated.
FEBS 26037 12-4-02
Y. Chen et al./FEBS Letters 517 (2002) 277^280278
3.3. TGF-L-facilitated secretion of LTBP-3 is dependent on the
formation of a disul¢de bond between Cys33 of the LAP
and cysteines in LTBP-3
It has been shown that LTBP-1 associates with TGF-L1
through the Cys33 of LAP bonding with cysteine(s) in the
CR3 domain [7,9]. We asked whether the TGF-L1-assisted
secretion of LTBP-3 is dependent on the formation of disul-
¢de bonds between LTBP-3 and Cys33 of the TGF-L1 LAP.
Cells were cotransfected with a TGF-L1 cDNA containing a
Cys33CSer mutation (TGF-L1C33S) and an LTBP-3 cDNA.
The mutant TGF-L1 SLC was secreted, but it did not pro-
mote the secretion of LTBP-3, as no LLC was detected in the
conditioned medium by immunoblotting (Fig. 2). Cotransfec-
tion of cells with the truncated LTBP-3 cDNA L3LEGCR4
and TGF-L1C33S yielded a similar result (Fig. 2). These re-
sults indicate that TGF-L-enhanced secretion of LTBP-3 is
dependent upon the formation of disul¢de bonds between
Cys33 of the LAP and cysteine(s) in LTBP-3.
Fig. 2. Coexpression with TGF-L1 Cys33CSer does not help
LTBP-3 secretion. The empty vector (pcNDA3), vector with a
cDNA encoding full-length LTBP-3 or a vector with cDNA encod-
ing L3LEGCR4 were transfected into 293T cells alone, together
with wild-type TGF-L1 cDNA or with a mutant Cys33CSer TGF-
L1 cDNA as indicated. Conditioned media were collected 48 h after
transfection, separated by SDS^PAGE under non-reducing condi-
tions, transferred to nitrocellulose membrane and blotted with anti-
body against TGF-L1 LAP.
Fig. 3. Schematic description of the LTBP-3 and LTBP-3/LTBP-1 constructs and in£uence of di¡erent regions of LTBP-3 and LTBP-1 on the
secretion of LTBP-3. A: Description of constructs. B^G: Constructs encoding truncated LTBP-3 or chimeras of LTBP-3/LTBP-1 were trans-
fected into 293T cells. Conditioned media and whole cell extract were collected 48 h after transfection, separated on SDS^PAGE under reduc-
ing conditions and revealed by Western blotting using HA antibody. B, D, F: Conditioned medium; C, E, G: cell lysate.
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3.4. Secretion of truncated forms of LTBP-3 with
LTBP-3/LTBP-1
To identify the region(s) of LTBP-3 that regulate its secre-
tion, we designed a number of expression cassettes that en-
coded either truncated LTBP-3 forms or chimeric forms of
LTBP-3 plus LTBP-1 (Fig. 3).
With constructs 1^5, representing large regions of LTBP-3,
only the N-terminal portion of LTBP-3 (L3NCR2, construct
2) was secreted (Fig. 3B). The failure to detect these proteins
in the conditioned medium was not due to poor expression as
immunoreactive protein was found in the cell extracts of cells
transfected with all constructs (Fig. 3C). Interestingly, the
proteins that were not secreted (encoded by constructs 1, 3,
4, 5) all have in common the LAP binding domain of LTBP-3.
To further our analysis, smaller fragments of the C-terminal
region of LTBP-3 (constructs 6^10) were expressed and the
conditioned medium monitored for secreted protein (Fig.
3A,D). The CR3 or CR4 region either alone (L3CR3, con-
struct 7; L3CR4, construct 8) or together with the two inter-
vening EGF-like domains (L3CR34, construct 6) are all
secreted (Fig. 3D). If the EGF-like repeats at the most C-ter-
minus are added to L3CR34 (L3CR3C, construct 5), this pro-
tein is not secreted (Fig. 3B). These results suggest that the
two terminal EGF-like domains control secretion. Interest-
ingly, when these two domains are combined with either
CR3 (L3CR3E2C, construct 9) or with CR4 (L3CR4E2C,
construct 10) secretion is normal. These results indicate that
the two EGF-like repeats at the C-terminus hinder the secre-
tion of LTBP-3 but only when both CR3 and CR4 are
present. The long EGF-like repeat stretch in combination
with L3CR34 (L3LEGCR4, construct 4) (Fig. 3B) also blocks
secretion, suggesting that this N-terminal sequence is interac-
tive with CR34. Thus, both £anking domains of L3CR34 may
participate in regulating LTBP-3 secretion.
Many truncated forms of LTBP-1 have been described, and
all have been reported to be secreted [7,9,11]. Therefore, we
constructed chimeras combining di¡erent regions of LTBP-3
and LTBP-1 to test whether the regulatory domains of LTBP-
3 acted in a dominant fashion, i.e. blocked the secretion of
LTBP-1 domains (Fig. 3F). When the last two EGF-like re-
peats of LTBP-1 are added to L3CR34 the resulting chimeric
construct L3CR34.L1E2C (construct 13) is secreted (Fig. 3F).
Similarly, when the last two EGF-like domains of LTBP-3 are
added to the carboxy-terminus of L1CR34 (construct 11, the
LTBP-1 equivalent of construct 6) the resulting chimeric pro-
tein (L1CR34.L3E2C, construct 15) is also e⁄ciently secreted.
These results are in contrast to the inability of the correspond-
ing protein derived entirely from LTBP-3, L3CR3C (construct
5), to be secreted. Therefore, the failure of L3CR3C to be
secreted is the result of speci¢c interactions between
L3CR34 and EGF-like domains 13, 14 of LTBP-3 as neither
domain acts in a dominant fashion. When the long stretch of
EGF-like repeats of LTBP-1 is linked to L3CR34 (construct
6), the resulting protein, L1LEG.L3CR34 (construct 12), is
not secreted. Similarly, when the long stretch of EGF-like
repeats of LTBP-3 is added to L1CR34 (construct 11), the
resulting chimera, L3LEG.L1CR34 (construct 14), is also
not secreted (Fig. 3F). However, similar constructs derived
only from the LTBP-1 sequence are e⁄ciently secreted. There-
fore, a dominant regulatory role is implied for both the stretch
of EGF-like repeats and, in this context, the L3CR34 of
LTBP-3. Finally, the protein products of all constructs (con-
structs 1^15) are secreted when coexpressed with latent TGF-
L (data not shown). Thus, we believe that the covalent inter-
action between LAP and LTBP-3 prevents the regulatory do-
mains of LTBP-3 from interacting and thereby allows secre-
tion.
4. Discussion
Like LTBP-1, LTBP-3 has multiple EGF-like and CR do-
mains. The full-length and many truncated forms of LTBP-1
have all been reported to be well secreted. Interestingly,
LTBP-3 forms intracellular aggregates under the same condi-
tions that permit LTBP-1 to be secreted. It is intriguing that
these two proteins, which are so similar in their overall do-
main structure, behave so di¡erently with respect to secretion.
Our results indicate that LTBP-3 cannot be secreted from
the cell in a free form and that both the long stretch of EGF-
like repeats and the two EGF-like repeats at the C-terminus
hinder secretion. Miyazono et al. demonstrated that latent
TGF-L1 was secreted very slowly without LTBP-1 and con-
tained incorrect disul¢de bonding [5]. When coexpressed,
LTBP-1 assisted the assembly and secretion of the TGF-L1
LLC. Here, we show that when coexpressed with TGF-L1,
LTBP-3 is secreted as the LLC. It is interesting that through
this association, TGF-L1 coordinates the folding and secretion
of LTBP-3. When Cys33, the residue critical for TGF-L LAP
binding to LTBP, is mutated, the association of LTBP and
LAP is abolished, and the mutant TGF-L1 does not assist
LTBP-3 secretion. This demonstrates that this disul¢de bond-
ing between TGF-L1 and LTBP-3 is critical for this ‘chaper-
one function’ of TGF-L1. These results imply that both TGF-
L and LTBP may function as chaperones for each other de-
pending upon the LTBP isoforms involved. It is possible that
this requirement for pairing of TGF-L and LTBP-3 serves as a
mechanism to regulate the extracellular availability of these
proteins.
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